01.06.2026 • Product

ReduCO₂: FLTMC Finalist

ReduCO₂ is one of the finalists for the From Lab to Market Challenge.

Co-Founders
L-R: Andreas Hettmann, Stefan Pitsch, and Lotta Ternieten, Co-Founders, ReduCO₂
© ReduCO₂

We spoke with Lotta Ternieten, Stefan Pitsch, and Andreas Hettmann (Co-Founders) about ReduCO₂, one of the finalists in the From Lab to Market Challenge. 

CHEManager: What is your technology, and what makes it work?

Lotta Ternieten, Stefan Pitsch, & Andreas Hettmann: ReduCO₂ transforms industrial CO₂ and hydrogen into high-purity graphite using a reactor process inspired by natural graphite formation. By replicating geological carbon crystallization under controlled conditions, we selectively grow battery-grade graphite while avoiding mining, toxic precursors and rare catalytic metals. The result is a scalable, cleaner and locally producible critical raw material.

What problem does your technology solve, and what is the business potential?

L. Ternieten, S. Pitsch, & A. Hettmann: ReduCO₂ addresses the growing shortage of high-purity graphite, a critical raw material for batteries and clean technologies. Today, over 90% of refined graphite is produced in China, creating supply risks and geopolitical dependence, while conventional production is highly polluting. We offer a scalable, local and cleaner alternative for a global graphite market projected to exceed USD 20 billion by 2030 as demand increasingly outpaces supply.

What's the next milestone your team is working towards?

L. Ternieten, S. Pitsch, & A. Hettmann: Our next milestone is moving from laboratory validation to pilot-scale development by demonstrating continuous production of high-purity graphite from CO₂ and securing our first industrial partnerships. We welcome conversations with investors, strategic partners, and organizations interested in building a resilient European graphite supply chain.


Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read